Update on the use of biologics in primary systemic vasculitides

References

• Fries JF, Hunder GG, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum.33(8), 1135–1136 (1990).
   PubMedGoogle Scholar
• Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum.37(2), 187–192 (1994).
   PubMed Web of Science ®Google Scholar
• Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann. Intern. Med.129(5), 345–352 (1998).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum.40(12), 2187–2198 (1997).
   PubMed Web of Science ®Google Scholar
• Haubitz M, Schellong S, Gobel U et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum.41(10), 1835–1844 (1998).
   PubMedGoogle Scholar
• De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.52(8), 2461–2469 (2005).
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med.349(1), 36–44 (2003).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med.347(4), 261–271 (2002).
   PubMed Web of Science ®Google Scholar
• Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J. Clin. Pathol.55(7), 481–486 (2002).
   PubMed Web of Science ®Google Scholar
• Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum.42(12), 2507–2516 (1999).
   PubMed Web of Science ®Google Scholar
• Knobler RL, Panitch HS, Braheny SL et al. Systemic α-interferon therapy of multiple sclerosis. Neurology34(10), 1273–1279 (1984).
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343(22), 1594–1602 (2000).
   PubMed Web of Science ®Google Scholar
• Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum.53(1), 93–99 (2005).
   PubMed Web of Science ®Google Scholar
• Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum.37(7), 1007–1012 (1994).
   PubMedGoogle Scholar
• Ramstead CL, Patel AD. Giant cell arteritis in a neuro–ophthalmology clinic in Saskatoon, 1998–2003. Can. J. Ophthalmol.42(2), 295–298 (2007).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Influence of age, sex, and place of residence on clinical expression of giant cell arteritis in northwest Spain. J. Rheumatol.30(7), 1548–1551 (2003).
   PubMedGoogle Scholar
• Salvarani C, Macchioni PL, Tartoni PL et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin. Exp. Rheumatol.5(3), 205–215 (1987).
   PubMed Web of Science ®Google Scholar
• Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br. J. Rheumatol.33(10), 938–941 (1994).
   PubMedGoogle Scholar
• Koldingsnes W, Nossent H. Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheum.43(11), 2481–2487 (2000).
   PubMed Web of Science ®Google Scholar
• Carruthers DM, Watts RA, Symmons DP, Scott DG. Wegener’s granulomatosis – increased incidence or increased recognition? Br. J. Rheumatol.35(2), 142–145 (1996).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann. Rheum. Dis.60(4), 367–371 (2001).
   PubMed Web of Science ®Google Scholar
• Rajala SA, Ahvenainen JE, Mattila KJ, Saarni MI. Incidence and survival rate in cases of biopsy-proven temporal arteritis. Scand. J. Rheumatol.22(6), 289–291 (1993).
   PubMed Web of Science ®Google Scholar
• Selga D, Mohammad A, Sturfelt G, Segelmark M. Polyarteritis nodosa when applying the Chapel Hill nomenclature – a descriptive study on ten patients. Rheumatology (Oxford)45(10), 1276–12781 (2006).
   PubMed Web of Science ®Google Scholar
• Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels (Suppl. 7), 11–17 (1992).
   Google Scholar
• Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case–control study. Arthritis Rheum.48(3), 814–823 (2003).
   PubMed Web of Science ®Google Scholar
• Pfister H, Ollert M, Frohlich LF et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood104(5), 1411–1418 (2004).
   PubMed Web of Science ®Google Scholar
• Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin. Exp. Immunol.81(2), 311–314 (1990).
   PubMedGoogle Scholar
• Komocsi A, Lamprecht P, Csernok E et al. Peripheral blood and granuloma CD4+CD28- T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener’s granulomatosis. Am. J. Pathol.160(5), 1717–1724 (2002).
   PubMed Web of Science ®Google Scholar
• Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin. Exp. Immunol.95(2), 244–250 (1994).
   PubMed Web of Science ®Google Scholar
• Takizawa M, Maguchi S, Nakamaru Y, Miyatake Y, Fukuda S, Inuyama Y. Correlation between the levels of circulating adhesion molecules and PR3-ANCA in Wegener’s granulomatosis. Auris Nasus Larynx (28 Suppl.), S59–S62 (2001).
   Google Scholar
• Moosig F, Csernok E, Kumanovics G, Gross WL. Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-α (TNF-α). Clin. Exp. Immunol.122(3), 499–503 (2000).
   PubMedGoogle Scholar
• van Rossum AP, Limburg PC, Kallenberg CG. Activation, apoptosis, and clearance of neutrophils in Wegener’s granulomatosis. Ann. NY Acad. Sci.1051, 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces β2 integrin and CXC chemokine-dependent neutrophil–endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J. Leukoc. Biol.77(1), 33–43 (2005).
   PubMed Web of Science ®Google Scholar
• Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener’s granulomatosis. N. Engl. J. Med.284(17), 938–942 (1971).
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med.98(1), 76–85 (1983).
   PubMed Web of Science ®Google Scholar
• de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant.16(10), 2018–2027 (2001).
   PubMed Web of Science ®Google Scholar
• Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum.31(4), 465–470 (1988).
   PubMed Web of Science ®Google Scholar
• Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med.124(5), 477–484 (1996).
   PubMed Web of Science ®Google Scholar
• Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol.18(7), 2180–2188 (2007).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Fain O, Lhote F et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum.35(2), 208–215 (1992).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum.38(11), 1638–1645 (1995).
   PubMed Web of Science ®Google Scholar
• Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann. Rheum. Dis.66(6), 798–802 (2007).
   PubMed Web of Science ®Google Scholar
• Birck R, Warnatz K, Lorenz HM et al. 15-deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol.14(2), 440–447 (2003).
   PubMed Web of Science ®Google Scholar
• Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am. J. Med.114(6), 463–469 (2003).
   PubMed Web of Science ®Google Scholar
• Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum.51(2), 269–273 (2004).
   PubMed Web of Science ®Google Scholar
• Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am. J. Kidney Dis.47(1), 15–23 (2006).
   PubMed Web of Science ®Google Scholar
• Metzler C, Miehle N, Manger K et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford)46(7), 1087–1091 (2007).
   PubMed Web of Science ®Google Scholar
• Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin. Pract.102(3–4), c100–c107 (2006).
   PubMedGoogle Scholar
• Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener’s granulomatosis. J. Rheumatol.30(1), 80–88 (2003).
   PubMedGoogle Scholar
• Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med.143(9), 621–631 (2005).
   PubMed Web of Science ®Google Scholar
• Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum.40(2), 371–380 (1997).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Mahr A et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum.49(1), 93–100 (2003).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore)78(1), 26–37 (1999).
   PubMed Web of Science ®Google Scholar
• Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis.66(5), 605–617 (2007).
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Hellmich B, Jayne D, Flossmann O, Luqmani R. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin. Exp. Rheumatol.24(6 Suppl. 43), S93–S98 (2006).
   PubMedGoogle Scholar
• Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N. Engl. J. Med.352(4), 351–361 (2005).
   PubMed Web of Science ®Google Scholar
• Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum.44(5), 1149–1154 (2001).
   PubMed Web of Science ®Google Scholar
• Stone JH, Holbrook JT, Marriott MA et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum.54(5), 1608–1618 (2006).
   PubMed Web of Science ®Google Scholar
• Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFα blockade in relapsing vasculitis. Ann. Rheum. Dis.61(6), 559 (2002).
   PubMedGoogle Scholar
• Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford)41(10), 1126–1132 (2002).
   PubMed Web of Science ®Google Scholar
• Booth A, Harper L, Hammad T et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol.15(3), 717–721 (2004).
   PubMed Web of Science ®Google Scholar
• Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford)41(11), 1303–1307 (2002).
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {α} blockade in Wegener’s granulomatosis. Ann. Rheum. Dis. (64 Suppl. 4), iv31–iv36 (2005).
   PubMedGoogle Scholar
• Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation109(14), 1718–1723 (2004).
   PubMed Web of Science ®Google Scholar
• Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med.173(2), 180–187 (2006).
   PubMed Web of Science ®Google Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.52(1), 262–268 (2005).
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford)45(11), 1432–1436 (2006).
   PubMed Web of Science ®Google Scholar
• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum.54(9), 2970–2982 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int.65(4), 1440–1448 (2004).
   PubMed Web of Science ®Google Scholar
• Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B. The Austrian Immunoglobulin in MS (AIMS) Study: final analysis. Mult. Scler. (6 Suppl. 2), S9–S13 (2000).
   Google Scholar
• Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol.41(6), 789–796 (1997).
   PubMed Web of Science ®Google Scholar
• Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barre syndrome. Plasma Exchange/Sandoglobulin Guillain–Barre Syndrome Trial Group. Lancet349(9047), 225–230 (1997).
   PubMed Web of Science ®Google Scholar
• Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM93(7), 433–439 (2000).
   PubMed Web of Science ®Google Scholar
• Muso E, Ito-Ihara T, Ono T et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn. J. Infect. Dis.57(5), S17–S18 (2004).
   PubMedGoogle Scholar
• Tatsis E, Schnabel A, Gross WL. Interferon-α treatment of four patients with the Churg–Strauss syndrome. Ann. Intern. Med.129(5), 370–374 (1998).
   PubMed Web of Science ®Google Scholar
• Metzler C, Lamprecht P, Hellmich B, Reuter M, Arlt AC, Gross WL. Leucoencephalopathy after treatment of Churg–Strauss syndrome with interferon α. Ann. Rheum. Dis.64(8), 1242–1243 (2005).
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Cohen P et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore)74(5), 238–253 (1995).
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Fenili D et al. Interferon α-2a therapy in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med.330(11), 751–756 (1994).
   PubMed Web of Science ®Google Scholar
• Shiota Y, Matsumoto H, Kanehisa Y et al. Serum interleukin-5 levels in a case with allergic granulomatous angiitis. Intern. Med.36(10), 709–711 (1997).
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Nakagami R, Morioka J et al. Interleukins in Churg–Strauss syndrome. Allergy55(8), 785–787 (2000).
   PubMedGoogle Scholar
• Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg–Strauss syndrome. Ann. NY Acad. Sci.1051, 121–131 (2005).
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA (2002) step 4 treatment): INNOVATE. Allergy60(3), 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months’ administration of anti-IgE to a patient with Churg–Strauss syndrome. J. Allergy Clin. Immunol.119(5), 1279 (2007).
   PubMed Web of Science ®Google Scholar
• Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N. Engl. J. Med.355(12), 1281–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Casato M, Lagana B, Pucillo LP, Quinti I. Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia. N. Engl. J. Med.338(19), 1386–1387 (1998).
   PubMedGoogle Scholar
• Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am. J. Kidney Dis.43(5), e34–e38 (2004).
   PubMedGoogle Scholar
• Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann. Rheum. Dis.61(10), 922–924 (2002).
   PubMed Web of Science ®Google Scholar
• Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol. Dial. Transplant.20(1), 213–216 (2005).
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood101(10), 3827–3834 (2003).
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood101(10), 3818–3826 (2003).
   PubMed Web of Science ®Google Scholar
• Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann. Intern. Med.82(5), 613–618 (1975).
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum.46(5), 1309–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum.49(5), 703–708 (2003).
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum.56(8), 2789–2797 (2007).
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology112(6), 1098–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Foroozan R, Deramo VA, Buono LM et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology110(3), 539–542 (2003).
   PubMed Web of Science ®Google Scholar
• Liozon E, Herrmann F, Ly K et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am. J. Med.111(3), 211–217 (2001).
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum.37(4), 578–582 (1994).
   PubMed Web of Science ®Google Scholar
• Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J. Rheumatol.30(8), 1793–1798 (2003).
   PubMed Web of Science ®Google Scholar
• Airo P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford)41(3), 347–349 (2002).
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum.44(12), 2933–2935 (2001).
   PubMed Web of Science ®Google Scholar
• Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J. Rheumatol.31(7), 1467 (2004).
   PubMed Web of Science ®Google Scholar
• Docken WP. Treatment of resistant giant cell arteritis with etanercept. Ann. Rheum. Dis.63(4), 469–470 (2004).
   PubMed Web of Science ®Google Scholar
• Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum.49(6), 826–837 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin. Rheumatol.26(8), 1353–1355 (2006).
   PubMedGoogle Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med.146(9), 621–630 (2007).
   PubMed Web of Science ®Google Scholar
• Luqmani R. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward? Ann. Intern. Med.146(9), 674–676 (2007).
   PubMedGoogle Scholar
• Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann. Rheum. Dis.64(7), 1099–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum.50(7), 2296–2304 (2004).
   PubMed Web of Science ®Google Scholar
• Tato F, Rieger J, Hoffmann U. Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int. Angiol.24(3), 304–307 (2005).
   PubMedGoogle Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?” Clin. Immunol.117(3), 207–213 (2005).
   Google Scholar
• Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum.46(6), 1634–1642 (2002).
   PubMed Web of Science ®Google Scholar
• Dougados M, Betteridge N, Burmester GR et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann. Rheum. Dis.63(9), 1172–1176 (2004).
   PubMed Web of Science ®Google Scholar
• Exley AR, Carruthers DM, Luqmani RA et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM90(6), 391–399 (1997).
   PubMed Web of Science ®Google Scholar
• Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener’s granulomatosis. Rheumatology (Oxford)41(5), 572–581 (2002).
   PubMed Web of Science ®Google Scholar
• Lozano E, Segarra M, Garcia-tinez A, Hernandez-Rodriguez J, Cid MC. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis. Ann. Rheum. Dis. COI: ard.2007.070805v1 (Epub ahead of print) (2007).
   Google Scholar